Literature DB >> 15173004

Hypoxia increases heparanase-dependent tumor cell invasion, which can be inhibited by antiheparanase antibodies.

Xiaotong He1, Paul E C Brenchley, Gordon C Jayson, Lynne Hampson, John Davies, Ian N Hampson.   

Abstract

The beta-endoglucuronidase heparanase plays an important role in tumor invasion, a process that is significantly enhanced by hypoxia. We have used a strategy of stable transfection with antisense to derive ovarian carcinoma cell lines that express different levels of heparanase and used these to demonstrate that invasion correlates with heparanase activity. Secreted heparanase activity was increased by reduction, hypoxia, and growth of cells under reduced oxygen (1%) augmented heparanase activity and invasion, both of which are inhibited by treatment with antiheparanase antibodies. This is the first demonstration that heparanase activity may be regulated by microenvironmental redox conditions, which influence invasion, and that invasion can be blocked with specific heparanase-neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15173004     DOI: 10.1158/0008-5472.CAN-03-2718

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis.

Authors:  Marina Weissmann; Gil Arvatz; Netanel Horowitz; Sari Feld; Inna Naroditsky; Yi Zhang; Mary Ng; Edward Hammond; Eviatar Nevo; Israel Vlodavsky; Neta Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

2.  Chemical Tumor Biology of Heparan Sulfate Proteoglycans.

Authors:  Karthik Raman; Balagurunathan Kuberan
Journal:  Curr Chem Biol       Date:  2010-01-01

3.  Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy.

Authors:  Jun Zhang; Jianmin Yang; Xiaomei Han; Zhongsheng Zhao; Ling DU; Tong Yu; Huiju Wang
Journal:  Oncol Lett       Date:  2012-05-04       Impact factor: 2.967

4.  A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.

Authors:  Barbara Muz; Pilar de la Puente; Feda Azab; Micah John Luderer; Justin King; Ravi Vij; Abdel Kareem Azab
Journal:  Br J Haematol       Date:  2016-01-05       Impact factor: 6.998

5.  Expression and clinical significance of heparanase in neuroblastoma.

Authors:  Li-Duan Zheng; Qiang-Song Tong; Shao-Tao Tang; Zhi-Yong Du; Yuan Liu; Guo-Song Jiang; Jia-Bin Cai
Journal:  World J Pediatr       Date:  2009-08-20       Impact factor: 2.764

6.  Molecular structure of heparan sulfate from Spalax. Implications of heparanase and hypoxia.

Authors:  Elina Sandwall; Sabrina Bodevin; Nicola J Nasser; Eviatar Nevo; Aaron Avivi; Israel Vlodavsky; Jin-Ping Li
Journal:  J Biol Chem       Date:  2008-12-09       Impact factor: 5.157

7.  Hypoxia and the presence of human vascular endothelial cells affect prostate cancer cell invasion and metabolism.

Authors:  Ellen Ackerstaff; Dmitri Artemov; Robert J Gillies; Zaver M Bhujwalla
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

Review 8.  Heparanase: a target for drug discovery in cancer and inflammation.

Authors:  E A McKenzie
Journal:  Br J Pharmacol       Date:  2007-03-05       Impact factor: 8.739

9.  Development of novel single-stranded nucleic acid aptamers against the pro-angiogenic and metastatic enzyme heparanase (HPSE1).

Authors:  Suzanne C Simmons; Edward A McKenzie; Lynda K Harris; John D Aplin; Paul E Brenchley; Maria N Velasco-Garcia; Sotiris Missailidis
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

Review 10.  The Role of Heparanase and Sulfatases in the Modification of Heparan Sulfate Proteoglycans within the Tumor Microenvironment and Opportunities for Novel Cancer Therapeutics.

Authors:  Edward Hammond; Ashwani Khurana; Viji Shridhar; Keith Dredge
Journal:  Front Oncol       Date:  2014-07-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.